Skip to main content
. 2017 Jun 29;2017(6):CD011412. doi: 10.1002/14651858.CD011412.pub2

Table 7.

Reasons for withdrawal from allocated treatment

Reason for withdrawal Classification
for analysis
Randomised drug4b
CBZ PHB PHT VPS LTG OXC TPM GBP LEV ZNS Total
Adverse events Event 505 (45%) 24 (20%) 93 (35%) 132 (28%) 235 (41%) 56 (41%) 259 (48%) 73 (20%) 134 (39%) 31 (32%) 1542 (38%)
Inadequate response Event 232 (20%) 20 (16%) 46 (17%) 140 (29%) 144 (26%) 36 (26%) 148 (27%) 223 (62%) 89 (26%) 23 (24%) 1101 (27%)
Both adverse events and
inadequate response
Event 148 (13%) 51 (41%) 54 (20%) 107 (22%) 32 (6%) 11 (8%) 46 (8%) 32 (9%) 0 (0%) 0 (0%) 481 (12%)
Protocol violation/non compliance Event 102 (9%) 15 (12%) 41 (15%) 11 (2%) 68 (12%) 27 (20%) 0 (0%) 21 (6%) 21 (6%) 3 (3%) 309 (8%)
Withdrew consent Event 121 (11%) 13 (11%) 25 (9%) 64 (13%) 65 (11%) 2 (1%) 55 (10%) 4 (1%) 68 (20%) 35 (36%) 452 (11%)
Othera Event 29 (3%) 0 (0%) 7 (3%) 24 (5%) 26 (5%) 5 (4%) 37 (7%) 9 (2%) 32 (9%) 4 (4%) 173 (4%)
Total eventsb 1137 (35%) 123 (38%) 266 (31%) 478 (28%) 570 (29%) 137 (29%) 545 (47%) 362 (61%) 344 (27%) 96 (34%) 4058 (34%)
Illness or death Censored 34 (2%) 10 (5%) 17 (3%) 7 (1%) 20 (1%) 1 (0%) 10 (2%) 9 (4%) 0 (0%) 0 (0%) 108 (1%)
Remission of seizures Censored 49 (2%) 4 (2%) 38 (6%) 75 (6%) 40 (3%) 12 (4%) 44 (7%) 21 (9%) 0 (0%) 0 (0%) 283 (4%)
Lost to follow‐up Censored 81 (4%) 31 (16%) 51 (9%) 63 (5%) 33 (3%) 24 (7%) 18 (3%) 0 (0%) 41 (5%) 0 (0%) 342 (4%)
Otherc Censored 104 (5%) 6 (3%) 22 (4%) 82 (7%) 31 (2%) 5 (2%) 26 (4%) 26 (12%) 0 (0%) 25 (13%) 327 (4%)
Completed study Censored 1829 (87%) 139 (73%) 468 (79%) 949 (81%) 1272 (91%) 291 (87%) 501 (84%) 166 (75%) 868 (95%) 161 (87%) 6644 (86%)
Total censoredb 2097 (65%) 190 (62%) 596 (69%) 1176 (72%) 1396 (71%) 333 (71%) 599 (53%) 222 (39%) 909 (73%) 186 (66%) 7704 (66%)
Missingd 24 7 1 26 12 8 14 11 0 0 103
Totale 3258 320 863 1680 1978 478 1158 595 1253 282 11,865

CBZ: carbamazepine; GBP: gabapentin; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PHB: phenobarbitone; PHT: phenytoin; TPM: topiramate; VPS: sodium valproate; ZNS: zonisamide

aOther treatment‐related reasons included: physician's decision, drug‐related death, pregnancy or perceived remission, or non specific (drug‐related) reason. bProportions for specific reasons indicate proportion of total events or total censored. Proportion for total events and total censored indicate the proportion of total participants. cOther non treatment‐related reasons included: epilepsy diagnosis changed, participants developed other medical disorders including neurological and psychiatric disorders or non specific (non drug‐related) reason. dWe treated those with missing reasons for withdrawal as censored in analysis and performed a sensitivity analysis treating these individuals as having withdrawal 'events.' Results of sensitivity analysis were practically identical and conclusions unchanged so we have presented the results treating these individuals as censored. eFour studies did not contribute to analysis of time to withdrawal of allocated treatment (Banu 2007; Craig 1994; Ogunrin 2005; Pal 1998).